Patrícia Silva, PhD, director of science content —

Hospital readmissions for chronic obstructive pulmonary disease (COPD) are linked to readmissions for other conditions as well as patients’ own experiences while hospitalized, such as communication with nurses, staff responsiveness, pain management and discharge information. The study reporting the findings is titled “Chronic Obstructive Pulmonary Disease Readmissions and…

The COPD Foundation has established the JW Walsh Fund to Cure COPD in honor of its late founder and director emeritus John W. Walsh, who died on March 7 this year at the age of 68. The memorial fund was created as a way to honor Walsh’s commitment to…

Pulmatrix was granted an important patent from the European Union (EU) for its proprietary iSPERSE technology, a platform for inhaled drug delivery based on unique properties developed for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD). “This new patent shows our continued ability to obtain patents that protect…

AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…

Using Monaghan Medical’s Aerobika device as part of a treatment regimen may help reduce emergency room visits, hospital re-admissions and related costs, as well as the recurrence of exacerbations in patients with chronic obstructive pulmonary disease (COPD). The study reporting these findings, “A Real-World Study of 30-Day Exacerbation…

International Biophysics Corporation announced a revenue growth of 34% in 2016 due to a 53% increase in unit sales of the AffloVest and other surgical product lines in the United States. AffloVest is a lung clearance therapy for patients with respiratory diseases such as chronic obstructive pulmonary disease (COPD). “As we enter our…

Boehringer Ingelheim is partnering with Weill Cornell Medicine to discover new treatment approaches to potentially halt or reverse the progression of chronic obstructive pulmonary disease (COPD). The three-year cooperative agreement will combine the research of Weill Cornell Medicine’s Department of Genetic Medicine in novel therapeutic concepts for airway repair…

Each year, more than 10,000 generally healthy patients die within seven days after being discharged from a hospital emergency room, according to a recent analysis. Heart disease and chronic obstructive pulmonary disease (COPD) are the most common causes of death among these patients. A growing number of patients — nearly 20% of…

Speakers at the 13th Annual Asthma & COPD Conference on March 29-30 in London, England will discuss the latest developments in asthma and chronic obstructive pulmonary disease (COPD). This year’s event will gather industry leaders, scientists, and members of the community to debate and talk about the latest challenges in asthma and COPD. The…

People with chronic obstructive pulmonary disease (COPD) often have other chronic conditions, like heart disease, and those who are poor about keeping  up with treatments for these comorbidites are also less likely to adhere to their COPD medications, according to results of a U.S. study conducted by Boehringer Ingelheim and Humana. The study,  “…